Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency

NCT04352205 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04352205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04352205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
May 7, 2020
Completion date
January 19, 2024
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma, renal failure